The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD).
 
Dirk Schadendorf
Honoraria - 4SC; Agenus; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Japan; Erasca, Inc; immatics; Immunocore; InflarxGmbH; LabCorp; Merck Serono; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Novigenix; Pamgene; Pfizer; Philogen; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sanofi/Regeneron; Seagen; Sun Pharma; Ultimovacs
Consulting or Advisory Role - Agenus; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Erasca, Inc; immatics; Immunocore; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Pierre Fabre; Replimune; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi/Regeneron
Research Funding - Amgen (Inst); Array BioPharma/Pfizer (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
 
Hussein A. Tawbi
Consulting or Advisory Role - Boxer Capital; Bristol-Myers Squibb; Eisai; Genentech/Roche; Iovance Biotherapeutics; Jazz Pharmaceuticals; Karyopharm Therapeutics; Medicenna; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Dragonfly Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); RAPT Therapeutics (Inst)
 
Evan J. Lipson
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb; CareDX; Eisai; Genentech; HUYA Bioscience International; Immunocore; Instil Bio; Merck; Natera; Nektar; Novartis; OncoSec; Pfizer; Rain Therapeutics; Regeneron; Replimune; Sanofi
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Regeneron (Inst); Sanofi (Inst)
 
F. Stephen Hodi
Employment - Dana-Farber Cancer Institute
Leadership - Bicara Therapeutics
Stock and Other Ownership Interests - Apricity Health; Bicara Therapeutics; Pionyr; Torque
Consulting or Advisory Role - AstraZeneca; Bioentre; Bristol-Myers Squibb; Catalym; Checkpoint THerapeutics; Compass Therapeutics; Corner Therapeutics; Curis; Genentech/Roche; Gossamer Bio; Immunocore; Iovance Biotherapeutics; Kairos Therapeutics; Merck Sharp & Dohme; Novartis; Rheos Medicines; Surface Oncology; Zumutor Biologics
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Methods of Using Pembrolizumab and Trebananib (Inst); patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche
 
Paolo Antonio Ascierto
Consulting or Advisory Role - 4SC; AstraZeneca; Bayer; Bio-AI Health; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Idera; Immunocore; Italfarmaco; ITeos Therapeutics; Lunaphore Technologies; Medicenna; Merck Serono; Merck Sharp & Dohme; Nektar; Nouscom; Novartis; OncoSec; Pfizer; Pierre Fabre; Regeneron; Replimune; Roche/Genentech; Sandoz; Sanofi; Seagen; Sun Pharma; Ultimovacs; ValoTx
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bio-AI Health; Pfizer; Replimune
 
James Larkin
Honoraria - Agence Unik; Bristol-Myers Squibb; Cambridge Healthcare research; Eisai; Incyte; Merck Serono; Novartis; Pfizer; RCGP; Royal College of Physicians; touchEXPERTS; touchIME; VJOncology
Consulting or Advisory Role - Agence Unik; Apple Tree Partners; Aptitude Health; AstraZeneca; Bristol-Myers Squibb; Calithera Biosciences; Debiopharm Group; eCancer; Eisai; EUSA Pharma; GlaxoSmithKline; Goldman Sachs; Incyte; Insel Gruppe; iOnctura; Ipsen; Merck Serono; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche; Ultimovacs
Research Funding - Achilles Therapeutics (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Covance (Inst); Immunocore (Inst); MSD (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - ESMO; GlaxoSmithKline; immatics; Pierre Fabre; Roche/Genentech
 
Christopher D. Lao
Consulting or Advisory Role - BMS
Research Funding - Bristol-Myers Squibb; Genentech; Novartis; Oncosec
 
Jean-Jacques Grob
Consulting or Advisory Role - Amgen; BMS; Merck KGaA; MSD Oncology; Novartis; Philogen; Pierre fabre; Roche; Roche/Genentech; Sanofi; Sun Pharma; Ultimovacs
Speakers' Bureau - Novartis; Pierre Fabre
Travel, Accommodations, Expenses - BMS; MSD Oncology; Novartis; Pierre Fabre
 
Flavia Ejzykowicz
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Andriy Moshyk
Employment - Bristol Myers Squibb Foundation
Stock and Other Ownership Interests - Bristol Myers Squibb Foundation
 
Viviana Garcia Horton
Employment - I am an employee of Analysis Group, Inc., a consulting firm that regularly receives funding for the conduct of studies from a variety of healthcare companies.
Consulting or Advisory Role - Bristol Myers Squibb Foundation
Research Funding - Bristol Myers Squibb Foundation (Inst)
 
Jenny Zhou
Employment - I am an employee of Analysis Group, Inc., a consulting firm that regularly receives funding for the conduct of studies from a variety of healthcare companies.
 
Yiqiao Xin
Employment - I am an employee of Analysis Group, Inc., a consulting firm that regularly receives funding for the conduct of studies from a variety of healthcare companies.
Consulting or Advisory Role - Bristol Myers Squibb Foundation (Inst)
Research Funding - Bristol Myers Squibb Foundation (Inst)
 
Jennell Palaia
Employment - Bristol Myers Squibb Foundation
Stock and Other Ownership Interests - Bristol Myers Squibb Foundation
Research Funding - Bristol Myers Squibb Foundation (Inst)
 
Laura McDonald
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Sarah Keidel
Employment - Bristol-Myers Squibb/Celgene; GlaxoSmithKline (I)
Stock and Other Ownership Interests - Abbvie; Bristol-Myers Squibb/Celgene; GlaxoSmithKline (I)
 
Anthony Salvatore
Employment - Bristol Myers Squibb Foundation
Stock and Other Ownership Interests - Bristol Myers Squibb Foundation
 
Leon A. Sakkal
Employment - Bristol Myers Squibb Foundation
Stock and Other Ownership Interests - Bristol Myers Squibb Foundation
 
Georgina V. Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; AstraZeneca; Boehringer Ingelheim; Bristol Myers Squibb; Evaxion Biotech; Hexal; Highlight Therapeutics; Innovent Biologics; Merck Sharp & Dohme; Novartis; OncoSec; PHMR; Pierre Fabre; Provectus; QBiotics; Regeneron